Inify Laboratories AB, corp. no. 559345-4431, held its ordinary Shareholders’ Annual General Meeting at the company’s premises on May 16, 2023. A total of 34,075,774 shares were represented at the Annual General Meeting, corresponding to 75.3% of the total number of shares and votes. The AGM resolved, with the required majority, on all matters in accordance with the Board of Directors’s published proposal. Below is a summary of the main decisions made, for further details please refer to the notice available on the company’s website.
Adoption of the accounts
The Annual General Meeting adopted the balance sheet and income statement for the period 2021-11-10 – 2022-12-31.
Disposition of financial results
The Annual General Meeting resolved, in accordance with the Board of Director’s proposal, that the loss for the year be distributed according to the balance sheet.
Discharge from liability
The members of the Board of Directors and the CEO were discharged from liability.
Articles of association
The AGM resolved to adopt new Articles of Association in accordance with the Board of Director’s proposal.
Remuneration and auditors fees
Remuneration to the Board of Directors and auditors was resolved as follows:
- Remuneration to the Chairman of the Board is SEK 300,000 for the period until next AGM.
- Remuneration to other board members, who are not principal owners, is SEK 200,000 for the period until next AGM.
- Remuneration to the auditor is paid against invoice, after approval by the company.
Board of Directors and auditor
Board members Olof Sandén, Martin Ingvar and Magne Jordanger were re-elected as board members. Grant Thornton Sweden AB was re-elected as audit firm with Joakim Söderin as acting auditor.
For more information, please contact CEO Fredrik Palm () or visit https://www.inify.com
This information is subject to the disclosure requirements of sections 5-12 of the Norwegian Securities Trading Act.
About Inify Laboratories
Inify Laboratories is currently building and establishing an ultramodern laboratory that will provide cancer diagnostics within histopathology. Designed from scratch, it uses a fully digital, standardized and AI-supported workflow to optimize quality and shorten response times, initially within prostate cancer. The first laboratory, located at Campus Solna Sweden, is estimated to start offering services to both public and private healthcare providers before summer 2023.
The company originates from ContextVision, with nearly 40 years of experience within digital imaging for medical applications and became independent through a spin-off in February 2022. The company, based in Sweden, is listed on Euronext Growth Oslo under the ticker INIFY.
Attachment
View attachment